EPIX Pharmaceuticals, Inc.
4 Maguire Road
Lexington
Massachusetts
02421
United States
Tel: 781-761-7600
Fax: 781-761-7632
Website: http://www.epixpharma.com/
Email: info@epixpharma.com
About EPIX Pharmaceuticals, Inc.
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics, and Bayer Schering Pharma AG, Germany.
For more information about EPIX, please visit the company’s website at www.epixpharma.com.
181 articles about EPIX Pharmaceuticals, Inc.
-
Advanced Cardiac Therapeutics, Inc. Changes Name to EPIX Therapeutics, Inc.
8/13/2018
Announces FDA Approval to Begin Enrolling Persistent Atrial Fibrillation Subjects in Global IDE Study to Evaluate the DiamondTemp™ Ablation System
-
AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by EPIX Pharmaceuticals, Inc. and Amgen.
11/30/2011
-
S1P1 Lead Compounds, Assets Generated by EPIX Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
11/9/2011
-
Bristol-Myers Squibb Company Release: Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Bristol-Myers Squibb Company. and EPIX Pharmaceuticals, Inc., Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
11/3/2011
-
EPIX Pharmaceuticals, Inc. Release: Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale
10/26/2011
-
EPIX Pharmaceuticals, Inc. Release: S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis
10/18/2011
-
EPIX Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Imaging Agents to June 22, 2010
5/21/2010
-
EPIX Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
5/17/2010
-
EPIX Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
5/10/2010
-
EPIX Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
5/4/2010
-
EPIX Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
4/19/2010
-
EPIX Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of MS-325 MRI Imaging Agent
4/12/2010
-
EPIX Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of Its MRI Imaging Intellectual Properties
4/6/2010
-
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease From Oscient Pharmaceuticals Corporation And EPIX Pharmaceuticals, Inc.
12/16/2009
-
MicroDose Therapeutx (formerly MicroDose Technologies Inc) Acquires EPIX Pharmaceuticals, Inc. Portfolio of Compounds for Treatment of Chronic Constipation and Irritable Bowel Syndrome with Constipation (IBS-C)
12/1/2009
-
EPIX Pharmaceuticals, Inc. Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient
10/16/2009
-
EPIX Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009
10/1/2009
-
EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
8/25/2009
-
EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
8/4/2009
-
EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
7/22/2009